6 research outputs found
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0236-9"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional enhanced
digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides</p
Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-016-0195-6"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional enhanced
digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides<u></u></p>
<p> </p
Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine u100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
<p></p><p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-018-0478-1"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides<u></u></p><br><p></p
Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data
<p><b>Objectives:</b> Health economic analysis from a healthcare and societal point of view was conducted to assess the cost-effectiveness of insulin degludec (IDeg) after switching from other basal insulins in people with type 1 diabetes.</p> <p><b>Material and methods:</b> This was a prospective, open-label, single arm, observational follow-up from August 2013 to October 2015 of 476 consecutive patients at Danderyd Hospital (Stockholm, Sweden) who switched to IDeg from other basal insulins (99% basal insulin analogs). The IMS CORE Diabetes Model (CDM) was used to predict the cost-effectiveness of life-long treatment with IDeg vs. other basal insulins, based on a Swedish setting.</p> <p><b>Results:</b> Mean (SD) duration of follow-up was 21.7 (6.0) weeks. Mean HbA<sub>1c</sub> decreased by 2.7âmmol/mol, mean basal insulin dose decreased by 13.1% (<i>p</i>â<â.0001), and mean bolus insulin dose decreased by 7.5% (<i>p</i>â<â.0001) after switching. Frequencies of non-severe daytime hypoglycemia and non-severe nocturnal hypoglycemia decreased by 12% (<i>p</i>â=â.0127) and 53% (<i>p</i>â<â.0001) respectively and severe hypoglycemia was reduced by 62% (<i>p</i>â=â.0225). The CDM predicted a gain in life expectancy of 0.33 years, a discounted gain in quality-adjusted life-years (QALYs) of 0.54, and lower estimated direct lifetime healthcare costs of SEK 22,757 for patients switching to IDeg. The incremental cost-effectiveness ratio (ICER) showed IDeg as dominant (i.e. higher effectiveness with a lower cost). Sensitivity analyses confirmed the results.</p> <p><b>Conclusion:</b> Based on this prospective, real-world, follow-up and using the CDM, it was estimated that switching to IDeg from other basal insulins translated into QALY gains including improved life expectancy and health-related quality of life, as well as dominant ICER, meaning cost-savings for the healthcare system. However, the study is limited by its observational design. Extrapolation into the future is only estimated since the actual treatment effect cannot be projected with certainty.</p
DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec versus Insulin Glargine U100 in BasalâBolus Regimens for Type 2 Diabetes in the UK
<p><b>Article full text</b></p><p><br> </p><p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13300-018-0430-4">https://link.springer.com/article/10.1007/s13300-018-0430-4</a></p><p></p><p><br></p><p><b>Provide enhanced content for this
article</b></p><p><br></p><p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âÂÂmailto:[email protected]âÂÂ"><b>[email protected]</b></a>.</p><p><br></p><p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include,
but are not limited to:</p><p><br></p><p>⢠Slide decks</p><p>⢠Videos and animations</p><p>⢠Audio abstracts</p><p>
</p><p>⢠Audio slides</p>
<p><b> </b></p
Additional file 1 of Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimerâs disease
Additional file 1. Simulation of treatment effects. Single simulation â Cox proportional hazards model. Comparison of statistical power